Other

Armbruster Biotechnology Gmbh

Sulzer Medizinaltechnik Ag

Mats Paulsson

Franz Paul Armbruster

Markus Karmatschek

Ulf Joerg Forssmann

Franz Werner Nader

Martin R Berger

Peter Bittmann

Thomas Thaler

Neil Smyth

Daniel Aeschlimann

Sarolta Karpati

Miklos Sardy

Hans Jorg Hauselmann

Uwe Odenthal

The invention relates to a method of therapy against tumors and their metastases, which preferentially settle in bone tissue, comprising administering to a patient in need thereof an active ingredient which comprises at least one binding molecule that binds to human bone sialoprotein or a fragment thereof.

Method for treating tumors and their metastases

The invention relates to a medicament against tumors and their metastases, which preferentially settle in bone tissue, comprising as active ingredient at least one binding molecule which binds to bone sialoprotein or a fragment thereof in serum or plasma.

Medicament for treating tumours and their metastases

The invention relates to antibodies or a plurality of antibodies against human bone sialoprotein (BSP), characterized in that the antibodies bind to epitopes which are present only in human bone sialoprotein from tumor cells, the post-translational glycosylation of which is modified or incomplete in the region of amino acids of 120 to 135, containing the amino acids TGLAA (SEQ ID NO: 2), in comparison with normal bone sialoprotein from bones. The antibodies are put to use in an immunoassay for the diagnosis and prognosis of tumor diseases, in particular the diagnosis and prognosis of bone metastases in the case of primary breast carcinoma.

Determination of bone-sialoprotein in bodily fluids for oncological problems

Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis&#x2014;pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sj&#xf6;gren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.

Diagnosis of gluten sensitive enteropathy and other autoimmunopathies

This invention provides an implant (prosthesis) for the replacement of defective biological tissue part. In particular, the implants of this invention are well suited for the replacement of cartilage, more preferably for the replacement of articular cartilage. In one embodiment, the implants comprise a micromatrix constructed from an upper boundary layer and a lower boundary layer where the upper and said lower boundary layers are connected via an intermediate layer with fibers. The implant also includes a nanomatrix situated within the intermediate layer. The nanomatrix contains elements of a size on the order of magnitude of nanometers. The intermediate layer accommodates the nanomatrix such that, for a growing inner pressure the boundary layers are mutually held at a preset distance from one another.

Areal implant

Growing community of inventors

Cologne, Germany

Mats Paulsson